Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1984/000561external-prioritypatent/WO1984004327A1/en
Application filed by Harvard CollegefiledCriticalHarvard College
Publication of DK619984D0publicationCriticalpatent/DK619984D0/en
Publication of DK619984ApublicationCriticalpatent/DK619984A/en
Application grantedgrantedCritical
Publication of DK171710B1publicationCriticalpatent/DK171710B1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
A first glycoprotein having a molecular weight of approx. 61,000 - 68,000 daltons in MJ, C5-MJ, C91PL or HUT 102 cell lines, 46,000 - 48,000 of which is the unglycosolated moiety, is obtained from cells which are infected with human T cell leukaemia virus. A second glycoprotein having a molecular weight of approx. 45,000 - 52,000 daltons is also obtained from such cells and is to a large extent identical to the NH2-terminal end of the first glycoprotein. The presence, in a biological sample, of antibody against the antigenic determinant of one of these proteins is an indication of the presence of cells which are infected with human T cell leukaemia virus. A test for the antibody is a useful diagnostic procedure for determining such an infection in biological samples.
DK619984A1983-04-271984-12-21Polypeptide and process for detecting human T cell leukaemia virus
DK171710B1
(en)